GuidelineHPB : the official journal of the International Hepato Pancreato Biliary Association2010
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement.
Guideline in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 208 citations in OpenAlex.
- Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.Annals of surgical oncology · 2024Trial
- Article
- Establishing the Minimum Future Liver Remnant Volume for Safe Hepatectomy.Journal of the American College of Surgeons · 2026Article
- Long-term survival outcome of portal vein embolization in patients with perihilar cholangiocarcinoma: a retrospective cohort study.World journal of surgical oncology · 2025Article
- Liver hypertrophy techniques: a position paper from the Italian Group of Regenerative and Occlusive Worldwide-used techniques of hepatic Hypertrophy (I GROWtoH).Updates in surgery · 2025Article
- Iatrogenic Subcapsular Haematoma Leads to 151% Growth of Future Liver Remnant.Cardiovascular and interventional radiology · 2025Article
- Spleen volume after stage-I associated liver partition and portal vein ligation for staged hepatectomy predicts future liver remnant.Langenbeck's archives of surgery · 2025Article
- Role of liver augmentation prior to hepatic resection - a survey on standards, procedures, and indications in Germany, Switzerland, and Austria.Langenbeck's archives of surgery · 2024Article
- Multidisciplinary comprehensive treatment of massive hepatocellular carcinoma with hemorrhage: A case report and review of literature.World journal of gastrointestinal oncology · 2024Article
- Hepatocellular Carcinoma: Surgical Management and Evolving Therapies.Cancer treatment and research · 2024Review
- Hepatocellular Carcinoma from a Hepatologist's Perspective.Seminars in interventional radiology · 2023Review
- The application of high-performance ultrasound probes increases anatomic depiction in obese patients.Scientific reports · 2023Article
- How Much Is Enough? A Surgical Perspective on Imaging Modalities to Estimate Function and Volume of the Future Liver Remnant before Hepatic Resection.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Review
- Portal vein embolization failure: Current strategies and future perspectives to improve liver hypertrophy before major oncological liver resection.World journal of gastrointestinal oncology · 2022Review
- Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?Seminars in cancer biology · 2022Review
- Imaging-guided interventions modulating portal venous flow: Evidence and controversies.JHEP reports : innovation in hepatology · 2022Review
- Predictors of mortality within the first year post-hepatectomy for hepatocellular carcinoma.Journal of the Egyptian National Cancer Institute · 2022Article
- Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).Hepatobiliary surgery and nutrition · 2022Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staging of hepatocellular carcinoma (HCC) is complex and relies on multiple factors including tumor extent and hepatic function. No single staging system is applicable to all patients with HCC. The staging of the American Joint Committee on Cancer / International Union for Cancer Control should be used to predict outcome following resection or liver transplantation. The Barcelona Clinic Liver Cancer scheme is appropriate in patients with advanced HCC not candidate for surgery. Dual phase computed tomography or magnetic resonance imaging can be used for pretreatment assessment of tumor extent but the accuracy of these methods remains poor to characterize < 1 cm lesions. Assessment of tumor response should not rely only on tumor size and new imaging methods are available to evaluate response to therapy in HCC patients. Liver volumetry is part of the preoperative assessment of patients with HCC candidate for resection as it reflects liver function. Preoperative portal vein embolization is indicated in patients with small future liver remnant (≤ 20% in normal liver; ≤ 40% in fibrotic or cirrhotic liver). Tumor size is not a contraindication to liver resection. Liver resection can be proposed in selected patients with multifocal HCC. Besides tumor extent, surgical resection of HCC may be performed in selected patients with chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.